Skip to main content
Fig. 5 | Molecular Medicine

Fig. 5

From: Targeting the NAT10/NPM1 axis abrogates PD-L1 expression and improves the response to immune checkpoint blockade therapy

Fig. 5

NAT10 modulated CD8 + T-cell infiltration and activity in vivo. A MC38 cells were stably transfected with control shRNA (sh-nc) or NAT10 shRNA. NAT10 and PD-L1 expression was measured by western blotting. B Pictures of the tumors excised after 21 days (n = 7). C The average tumor volume of each group over time is shown. D–F TILs in the tumors of each group (n = 4) were analyzed by flow cytometry. CD8+ cells (D), CD107+CD8+ cells (E) and CD69+CD8+ cells (F) were gated on CD45. Data are presented as the mean ± s.d. *P < 0.05, **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not significantly different

Back to article page